Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations

BioCentury This Week

English - June 10, 2024 23:00 - 29 minutes - 20.3 MB - ★★★★★ - 11 ratings
Science biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Ep.234 - Biotech M&A, Biosecure Expands & ASCO Update

Next Episode: Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma

A snub by an FDA advisory committee for an MDMA-psychotherapy combination is unlikely to read through to other psychedelic therapies in the pipeline. On the BioCentury This Week podcast, BioCentury’s editors discuss the shortcomings of the Lykos Therapeutics product’s clinical development program and why other psychedelics likely won’t face the same hurdles. The editors also assess FDA’s new platform technology designation and the first-in-human clinical trials described at this year’s American Society of Clinical Oncology (ASCO) meeting. This week’s podcast is sponsored by Nxera Pharma.

View full story: https://www.biocentury.com/article/652639

00:01 - Sponsor Message: Nxera Pharma
01:41 - Psychedelic Setback
12:38 - FDA's Platform Play
21:39 - ASCO Innovations